PMID- 22784518
OWN - NLM
STAT- MEDLINE
DCOM- 20121024
LR  - 20170214
IS  - 1203-4754 (Print)
IS  - 1203-4754 (Linking)
VI  - 16
IP  - 4
DP  - 2012 Jul-Aug
TI  - Safety and efficacy of adalimumab for the treatment of severe alopecia areata: 
      case series of three patients.
PG  - 257-60
AB  - BACKGROUND: Current therapeutic options for extensive alopecia areata (AA) often 
      lead to disappointing results. OBJECTIVE: To study the efficacy and safety of 
      adalimumab in patients with severe AA. METHODS: This was a prospective, 
      open-label, single-center, pilot study. Three subjects of the planned 10 were 
      enrolled and received two weekly subcutaneous (SC) loading doses of adalimumab 80 
      mg followed by 40 mg SC every week for 6 months. Patients were evaluated for 
      efficacy and safety on a monthly basis. RESULTS: Enrolment in this trial was 
      stopped following publication of studies showing no improvement in patients with 
      AA treated with tumor necrosis factor alpha antagonists. One patient had a favorable 
      response to adalimumab, whereas the two other patients had no benefit from the 
      therapy. Adalimumab was well tolerated by patients with AA. CONCLUSION: 
      Adalimumab was well tolerated in patients with AA but did not induce clinically 
      significant hair regrowth.
FAU - Bolduc, Chantal
AU  - Bolduc C
AD  - Innovaderm Resarch Inc, Monreal, QC.
FAU - Bissonnette, Robert
AU  - Bissonnette R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cutan Med Surg
JT  - Journal of cutaneous medicine and surgery
JID - 9614685
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Alopecia Areata/*drug therapy
MH  - Anti-Inflammatory Agents/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2012/07/13 06:00
MHDA- 2012/10/25 06:00
CRDT- 2012/07/13 06:00
PHST- 2012/07/13 06:00 [entrez]
PHST- 2012/07/13 06:00 [pubmed]
PHST- 2012/10/25 06:00 [medline]
AID - 10.1177/120347541201600407 [doi]
PST - ppublish
SO  - J Cutan Med Surg. 2012 Jul-Aug;16(4):257-60. doi: 10.1177/120347541201600407.